Abstract
A glucose-mediated drug delivery system would be highly satisfactory for diabetes diagnosis since it can intelligently release drug based on blood glucose levels. Herein, a glucose-responsive drug delivery system by integrating glucose-responsive poly(3-acrylamidophenylboronic acid) (PAPBA) functionalized hollow mesoporous silica nanoparticles (HMSNs) with transcutaneous microneedles (MNs) has been designed. The grafted PAPBA serves as gatekeeper to prevent drug release from HMSNs at normoglycemic levels. In contrast, faster drug release is detected at a typical hyperglycemic level, which is due to the change of hydrophilicity of PAPBA at high glucose concentration. After transdermal administration to diabetic rats, an effective hypoglycemic effect is achieved compared with that of subcutaneous injection. These observations indicate that the designed glucose-responsive drug delivery system has a potential application in diabetes treatment.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
